You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Prostate cancer

Degarelix for treating advanced hormone-dependent prostate cancer

  • Technology appraisal guidance
  • Reference number: TA404
  • Published:  24 August 2016
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Prostate cancer (advanced, hormone dependent) - degarelix depot: committee papers

01 – Letter from Ferring Pharmaceuticals following appeal panel decision

02 – Decision Support Unit report prepared by SCHARR

Prostate cancer (advanced, hormone dependent) - degarelix depot: committee papers Prostate cancer (advanced, hormone dependent) - degarelix depot: committee papers
05 June 2015
(333.89 Kb 37 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 03 June 2015

Back to top